Novavax to Participate in Upcoming Conferences
|Piper Sandler 32nd Annual
|Panel title:||The Road Ahead for COVID-19 Vaccines: What We Know and Questions Still to Be Answered into 2021|
Additional panelists: Moderna, Inc., Arcturus Therapeutics Holdings, Inc. and Altimmune, Inc.
This event is open to Piper Sandler clients
|Webcast:||A replay of the recorded fireside session is available through the events page of the Company’s website at ir.novavax.com for 90 days.|
|Participation:||Fireside chat and investor meetings|
|Live webcast:||www.novavax.com, “Investors”/ “Events”|
NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19. In preclinical trials, NVX-CoV2373 demonstrated induction of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In the Phase 1 portion of its Phase 1/2 clinical trial, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. NVX-CoV2373 is also being evaluated in a Phase 3 trial in the
Source: Novavax, Inc.